Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CSBR

Champions Oncology (CSBR) Stock Price, News & Analysis

Champions Oncology logo

About Champions Oncology Stock (NASDAQ:CSBR)

Advanced Chart

Key Stats

Today's Range
$9.00
$9.72
50-Day Range
$9.11
$10.96
52-Week Range
$3.60
$11.99
Volume
32,633 shs
Average Volume
18,414 shs
Market Capitalization
$94.81 million
P/E Ratio
21.50
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Champions Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

CSBR MarketRank™: 

Champions Oncology scored higher than 79% of companies evaluated by MarketBeat, and ranked 232nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Champions Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    Champions Oncology has a consensus price target of $12.00, representing about 74.4% upside from its current price of $6.88.

  • Amount of Analyst Coverage

    Champions Oncology has received no research coverage in the past 90 days.

  • Read more about Champions Oncology's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Champions Oncology is 21.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 278.04.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Champions Oncology is 21.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.15.

  • Price to Book Value per Share Ratio

    Champions Oncology has a P/B Ratio of 25.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.55% of the float of Champions Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Champions Oncology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Champions Oncology has recently decreased by 10.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Champions Oncology does not currently pay a dividend.

  • Dividend Growth

    Champions Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.55% of the float of Champions Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Champions Oncology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Champions Oncology has recently decreased by 10.31%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Champions Oncology insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Champions Oncology's insider trading history.
    Receive CSBR Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    CSBR Stock News Headlines

    Turn $1K into $50K with This DeFi Gem
    Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.tc pixel
    See More Headlines

    CSBR Stock Analysis - Frequently Asked Questions

    Champions Oncology, Inc. (NASDAQ:CSBR) announced its earnings results on Wednesday, July, 23rd. The biotechnology company reported ($0.13) EPS for the quarter. The biotechnology company had revenue of $12.35 million for the quarter. Champions Oncology had a trailing twelve-month return on equity of 196.12% and a net margin of 8.26%.
    Read the conference call transcript
    .

    Champions Oncology's top institutional investors include Jane Street Group LLC (0.13%) and XTX Topco Ltd (0.10%). Insiders that own company stock include Ronnie Morris and Daniel Newman Mendelson.
    View institutional ownership trends
    .

    Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY).

    Company Calendar

    Last Earnings
    7/23/2025
    Today
    9/06/2025
    Fiscal Year End
    4/30/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:CSBR
    CIK
    771856
    Employees
    143
    Year Founded
    2007

    Price Target and Rating

    High Price Target
    $12.00
    Low Price Target
    $12.00
    Potential Upside/Downside
    +74.4%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.06)
    Trailing P/E Ratio
    21.50
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $4.70 million
    Net Margins
    8.26%
    Pretax Margin
    8.12%
    Return on Equity
    196.12%
    Return on Assets
    16.62%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.94
    Quick Ratio
    0.94

    Sales & Book Value

    Annual Sales
    $56.94 million
    Price / Sales
    1.67
    Cash Flow
    $0.46 per share
    Price / Cash Flow
    15.08
    Book Value
    $0.27 per share
    Price / Book
    25.48

    Miscellaneous

    Outstanding Shares
    13,780,000
    Free Float
    7,305,000
    Market Cap
    $94.81 million
    Optionable
    Optionable
    Beta
    0.51

    Social Links

    7 Stocks to Ride The A.I. Megaboom Cover


    We are about to experience the greatest A.I. boom in stock market history...

    Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

    That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

    1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
    2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
    3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

    Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

    And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

    Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

    Get This Free Report

    This page (NASDAQ:CSBR) was last updated on 9/7/2025 by MarketBeat.com Staff
    From Our Partners